Table 2 Patient’s characteristics pre-intervention and 3 weeks post-intervention.
Pre-intervention | 3 Weeks post-intervention | |||||
|---|---|---|---|---|---|---|
PSMF (n = 10) | RYGB (n = 10) | SG (n = 10) | PSMF (n = 10) | RYGB (n = 10) | SG (n = 10) | |
Age (years) | 60.6 ± 3.9 | 52.5 ± 7.9 | 52.9 ± 10.0 | NA | NA | NA |
Female (n (%)) | 8 (80) | 5 (50) | 4 (40) | NA | NA | NA |
BMI (kg/m2) | 38.7 ± 4.1* | 41.3 ± 6.6 | 40.1 ± 7.9 | 37.0 ± 4.1† | 37.0 ± 5.7† | 36.8 ± 7.5† |
Weight (kg) | 105.2 ± 17.0 | 118.8 ± 18.2 | 122.4 ± 28.4 | 100.5 ± 15.8† | 106.3 ± 15.2† | 112.2 ± 25.9† |
Weight loss (%) | NA | NA | NA | 4.4 ± 1.8‡ | 10.4 ± 2.7 | 8.4 ± 2.7 |
Diabetes duration (years) | 16.3 ± 8.3* | 9.3 ± 7.8 | 13.5 ± 8.4 | NA | NA | NA |
HbA1c (%) | 9.3 ± 1.6* | 8.0 ± 1.8 | 8.7 ± 1.6 | NA | NA | NA |
HbA1c (mmol/mol) | 78 ± 18 | 64 ± 20 | 72 ± 18 | NA | NA | NA |
Metformin (n (%)) | 9 (90) | 8 (80) | 10 (100) | 7 (70) | 7 (70) | 10 (100) |
Sulfonylurea (n (%)) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
GLP-1 agonist (n (%)) | 0 (0) | 1 (10) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
DPP-IV inhibitor (n (%)) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Insulin bolus (IU) | 49.4 ± 41.3 | 37.1 ± 19.1 | 52.9 ± 23.5 | 22.4 ± 18.4† | 14.2 ± 7.7† | 17.8 ± 15.8† |
Insulin basal (IU) | 48.0 ± 19.9 | 42.1 ± 13.5 | 40.4 ± 19.1 | 45.5 ± 21.2 | 17.0 ± 4.1† | 29.1 ± 14.1† |
Fasting glucose (mg/dL) | 115.2 ± 10.0 | 109.0 ± 9.3 | 116.1 ± 15.5 | 107.5 ± 14.9 | 106.3 ± 17.6 | 95.2 ± 11.5† |
Fasting C-peptide (pmol/L) | 407.7 ± 145.7 | 648.2 ± 427.5 | 691.9 ± 347.0 | 501.7 ± 175.4 | 780.2 ± 333.6 | 760.6 ± 233.5 |
Fasting insulin (pmol/L) | 317.6 ± 343.4 | 179.4 ± 174.3 | 217.6 ± 166.1 | 234.9 ± 179.1 | 117.3 ± 59.1 | 78.4 ± 43.0† |
